The Evolution of Frontline Hodgkin Lymphoma Treatment
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Emerging Pomalidomide-Based Triplet Therapies for Multiple Myeloma
Pomalidomide-based triplet therapies appear safe, effective, and associated with improved outcomes compared with the current standard of care. -
Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results
One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results. -
Evaluating the Cost-Effectiveness of Acute Myeloid Leukemia Treatment
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia. -
Looking Back to Go Forward: CAR-T Cell Therapy in R/R CLL
Research suggests that ibrutinib may have the ability to alter the phenotype of a final CAR-T cell product.
HEMATOLOGIC CANCER NEWS
Phase 1/2 Study of Durvalumab and Tremelimumab in Pediatric Cancer
Trial to Assess Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Hodgkin Lymphoma
The Role of Direct Oral Anticoagulants in the Outpatient Setting Questioned
Number of Comorbidities Linked to Risk of Thromboembolism in Leukemia, Lymphoma
Gait Speed Effectively Predicts Clinical Outcomes in Older Patients With Hematologic Cancers
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
